APPA is aiming to integrate psychedelics into the US healthcare system and ensure safe access for all who can benefit from the treatments.
UK-based global nootropics company Puresport has had its Reishi, Cordyceps and Lion’s Mane supplements certified by Informed Sport, the gold-standard independent certification body.
Psyence Group has completed an export of psilocybin to Psilo Pharma from its federally licensed ISO22000 certified production facility in Southern Africa, through its research partner...
Cybin has entered into an agreement with Mindset Pharma to acquire an exclusive license to an extensive, targeted class of tryptamine-based molecules.
Origin Therapeutics’ portfolio company, Xpira Pharmaceuticals, has received FDA approval for its Psilocybin Trial IND Application.
University of Cincinnati postdoctoral researcher Neşe Devenot has stated that the field of psychedelics is fraught with ethical concerns and financial interests.
Revive Therapeutics has announced that it is working on its first Phase I/II clinical study to evaluate oral psilocybin in the treatment of methamphetamine use disorder.
Drug discovery and development company Mindset Pharma has filed for national patents protecting “Family 1” – second-generation psilocybin analogues – in 16 different countries, including South...
Awakn Life Sciences has signed the twelve month option agreement with a drug development company that will see its ketamine formulation and route of administration optimised...
Awakn Life Sciences has signed its first licensing partnership agreement in Canada with Ontario-based Wellbeings Pain Management and Dependency Clinic, which is focused on multi-disciplinary, evidence-based,...
